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Physical Intimacy of Breast Cancer 
Cells with Mesenchymal Stem Cells 
Elicits Trastuzumab Resistance 
through Src Activation
Amita Daverey1, Allison P Drain1 & Srivatsan Kidambi1,2,3
The development of resistance to trastuzumab is a major obstacle for lasting effective treatment 
of patients with ErbB2-overexpressing tumors. Here, we demonstrate that the physical contact of 
breast cancer cells with mesenchymal stem cells (MSCs) is a potential modulator of trastuzumab 
response by activation of nonreceptor tyrosine kinase c-Src and down regulation of phosphatase 
and tensin homolog (PTEN). Using an in vitro patterned breast cancer/MSC co-culture model, we 
find that the presence of MSCs results in Src activation that is missing in cancer cells monoculture, 
transwell co-culture, and cells treated with MSCs conditioned media. Interestingly, the co-culture 
model also results in PTEN loss and activation of PI3K/AKT pathway that has been demonstrated as 
fundamental proliferative and survival pathways in clinical settings. To our knowledge, this is the first 
report that showed PTEN loss without the use of chemical inhibitors, matrix stiffness, or silencing 
RNAs. In addition, breast cancer cells in co-culture with MSCs conferred trastuzumab resistance in 
vitro as observed in the lack of inhibition of proliferative and migrative properties of the cancer cells. 
Our findings show that MSCs are potent mediators of resistance to trastuzumab and might reveal 
targets to enhance trastuzumab efficacy in patients.
Human epidermal growth factor receptor-2 (HER-2 or ErbB2) gene is overexpressed in approximately 
20–25% of human breast cancers and is associated with poor clinical prognosis and survival1,2. Treatment 
with trastuzumab, a humanized antibody that targets HER-2, has dramatically altered the course of HER-2 
positive breast cancer patients. However, majority of the patients do not respond to initial treatment or 
develop resistance after continuous treatment of the drug3,4. Two major trastuzumab resistance mecha-
nisms have been proposed: (i) de novo resistance due to genetic alterations of receptor tyrosine kinases 
(RTKs) and their downstream signaling targets (such as phosphatase and tensin homolog (PTEN) loss 
and activation of the phosphoinositide 3-kinase (PI3K)); and (ii) acquired resistance primarily due to 
the acquisition of alternative RTK signaling activation that compensate for HER-2 inhibition after trastu-
zumab treatment3–5. Recent studies have highlighted a new resistance mechanism implicating nonrecep-
tor tyrosine kinase c-Src as a key modulator of trastuzumab response and a common node downstream 
of multiple trastuzumab- resistance pathways6–8. Increased activation of Src has been observed in both 
acquired and de novo trastuzumab-resistant cells and this activation regulates the loss of PTEN, thus 
promoting drug resistance. Moreover, in vitro and in vivo experimental results strongly indicate an 
important role of Src in the development and progression of breast cancer as well as a viable therapeutic 
option6–8. Despite these promising experimental data, the underlying molecular mechanisms of what 
might activate Src leading to trastuzumab resistance remains unclear.
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Tumor microenvironment has garnered the spotlight in recent years for its important role in tumor 
progression and drug resistance9–11. Tumors actively modulate their microenvironment by recruiting 
lymphocytes and macrophages12; vascular endothelial cells; and tumor-associated stromal cells such 
as tumor-associated fibroblasts (TAFs) and mesenchymal stem cells (MSCs)13,14. MSCs, in addition to 
other cells in the tumor microenvironment, have been identified as an important population of cells 
that modulate tumor progression and drug sensitivity15–17. Recent reports have demonstrated that MSCs 
are recruited in large numbers to the stroma of developing tumors18,19. Furthermore, MSCs integrate 
into tumor-associated stroma, and exhibit multiple regulatory functions in the tumor microenviron-
ment13,20,21. The bidirectional paracrine signaling between MSCs and breast cancer cells are found to 
stimulate tumor growth, enhance angiogenesis, and promote metastasis formation through the release 
of a large spectrum of growth factors and cytokines22–24. MSCs also promote tumor cell migration, an 
epithelial-to-mesenchymal transition (EMT), and increase chemoresistance in breast cancer cells15–17. 
Growth patterns of cancer cells in co-culture change from a clustered to a single cell distribution, and 
these morphological alterations have been related to a significant down regulation of cell adhesion mole-
cules E-cadherin and epithelial specific antigen (ESA)25. MSCs are also believed to modulate the response 
to drugs including trastuzumab by either direct cell-cell interactions with tumor cells, or by the local 
release of soluble factors such as interleukin-6, promoting survival and tumor growth15,26–28.
The growth- and metastasis-promoting effects of MSCs have been well documented22–24, but a possi-
ble role in drug resistance including activation of Src and downstream pathways has been only partially 
explored, and has been difficult to obtain. This is due, in part, to the complexity of recreating and isolat-
ing the cell-cell communications in clinical and in vivo models. Advances in humanized mouse models 
have closed this gap; however, the heterogeneity of the human xenografts grafted into the mouse models 
makes it challenging to study cell-cell communication in tumors. Primary human breast cancer cells have 
contributed to the advancement of our understanding of cancer biology, however, this system cannot 
evaluate interactions between carcinoma and intratumoral stromal cells. Co-culture compositions of two 
different cell type of cancer tissues i.e., breast cancer cells and stromal cells, were established in order 
to evaluate cell–cell interactions in tumor microenvironment. However, the use of random co-culture 
does not recreate the physiologically relevant interactions. Indirect co-culture method using transwell 
inserts provide valuable information on the role of secreted factors but the physical contact between the 
cells present in physiological conditions is missing. We and others have developed in vitro co-culture 
systems capable of engineering controlled environment of spatially defined micro-scale surfaces using 
microfabrication techniques29–33. This system provides an ideal platform to study the role of cell-cell 
communication on critical tissue function. In this study, we hypothesize that Src mediated trastuzumab 
resistance might be caused, at least in part, by cell-cell communication between MSCs and tumor cells, 
where in physical intimacy between the cells is the key factor. To test this hypothesis, we developed a 
co-culture system whereby HER-2 positive tumor cells are co-cultured with MSCs, and the ability of the 
MSCs to activate Src and modulate downstream drug resistance pathways is observed.
Results
Physical Contact of MSCs with Breast Cancer Cells Activates Src. To test the hypothesis that 
physical intimacy and not soluble factors from MSCs activates Src, we established four different systems 
to recreate these interactions. Human breast cancer cells were cultured 1) alone (monoculture); 2) treated 
with conditioned media from MSCs (MSCs-CM) to introduce secreted soluble factors into breast can-
cer cells; 3) co-culture of breast cancer cells with MSCs using transwell (Boyden Chamber) to monitor 
cell-cell interactions through soluble factors derived from each cells and 4) random co-culture with 
MSCs which contains the physical contact and ability to share soluble signaling factors (co-culture). We 
employed two developmentally distinct human breast cell lines for this study: 1) BT474 (HER2+ invasive 
breast cancer cells), and 2) 21MT-1 (stable patient-derived metastatic breast cancer cells isolated from 
the metastatic pleural effusion). We specifically chose 21MT-1 cells due to recent reports highlighting the 
21T cell line’s ability to mimic in vivo cancer development and behavior within the in vitro enviroment 
through stage specific cell proliferation, migration, morpholgy, polarization, and gene expression profiles, 
and its consequent potential for usage as a valuable translational disease model for breast cancer34. A sig-
nificant (p < 0.01) increase in Src protein expression was observed in random co-cultures of breast can-
cer cells and MSCs, while no significant change (p > 0.05) was observed in cells exposed to MSCs-CM, 
transwell co-culture, and monoculture of breast cancer cells (Fig. 1). Furthermore, no significant increase 
in Src expression was observed in breast cancer cells co-cultured with MCF10A cells (mammary epithe-
lial cells), suggesting that this is a MSC-specific phenomena (Supplementary Fig. 1). This data suggest 
that the physical contact of breast cancer cells with MSCs is critical for MSCs mediated regulation of Src, 
and one of the possible mechanisms for Src activation in aggressive breast cancers.
Establishing Patterned Co-culture of Breast Cancer Cells and MSCs. To further investigate the 
effect of interaction of MSCs with breast cancer cells, we established a patterned co-culture system of 
breast cancer cells with MSCs using polyelectrolyte multilayer (PEM) films. We have previously screened 
several polymers similar to self-assemble protein network found in extracellular matrix35. Among all pol-
ymers, poly(diallyldimethylammonium chloride) (PDAC) and poly(4-styrenesulfonic acid) (SPS) were 
selected due to their ability to produce most consistent observations with cell attachment (Fig. 2A). For 
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all experiments, 10 or 10.5 bilayers of PDAC/SPS were deposited on tissue culture polystyrene surfaces 
(TCPS) making SPS or PDAC as topmost layer and are designated as (PDAC/SPS)10 or (PDAC/SPS)10.5 
respectively. No difference in morphology and growth of BT-474, 21MT-1 and MSCs were observed 
when cells were grown on (PDAC/SPS)10 compared to control. Quantitative analysis of attachment of 
cells on PEM films indicated higher attachment on (PDAC/SPS)10 compared to (PDAC/SPS)10.5 (Fig. 2A 
and Supplementary Fig. 2). The specific protein markers for breast cancer cells (HER-2 expression) and 
for MSCs (CD166) remained unchanged on both polymer surfaces compared to control, suggesting that 
polymer surfaces do not influence the biology of the cells beyond the cell adhesion behavior (Fig. 2B).
The approach for developing the patterned co-culture of breast cancer cells and MSCs consisted of 
capitalizing upon the cell adhesive and resistive property of SPS and PDAC, respectively, as shown in 
Fig. 2C and Supplementary 3. Unlike random co-culture where interaction of two cells is difficult to con-
trol, patterned co-culture provides a highly controlled system where cell placement and precise cell-cell 
interaction can be tuned by varying size and shape of patterns on fabricated surfaces. Patterns were fully 
characterized before seeding cells on fabricated surfaces using negatively charged fluorescent dye and 
polystyrene carboxylate microparticles (data not shown). Breast cancer cells preferentially attached on 
the SPS patterns when they were seeded on the PEM surfaces (Fig. 2C). MSCs were subsequently seeded 
onto the patterns of breast cancer cells thus engineering patterned co-cultures of breast cancer cells and 
MSCs (Fig.  2C). We also measured the average percent coverage of breast cancer cells and MSCs in 
15 different patterns that demonstrated consistent patterning technique and development of patterned 
co-culture of breast cancer cells with MSCs (Supplementary Fig. 4).
MSCs induce Src Activation in Patterned Co-culture and not in Conditioned Media. Given 
our observation that MSCs induce Src activation in random co-culture, we tested that phenomenon in 
our patterned co-culture system as well. To investigate this, we probed breast cancer cells and MSCs 
using antibodies against Src (red) and CD166 (green) (Fig. 3A). Akin to random co-culture, breast cancer 
cells in co-culture with MSCs indicated higher Src expression compared to monoculture and breast can-
cer cells exposed to conditioned media from MSCs (MSCs-CM) (Fig. 3A, upper panel). Quantification 
of fluorescence intensity shows that the Src expression in co-cultures increased ∼ 2 fold compared to 
the monoculture (Fig. 3A, lower panel). In co-culture, MSCs also show Src expression, however, merge 
images indicated that majority of the Src fluorescence is from the breast cancer cells.
To further investigate how physical contact of MSCs regulates Src activation in breast cancer cells, 
we examined whether MSCs in co-culture with breast cancer cells may activate Src tyrosine kinase. 
To quantify the Src expression in breast cancer cells, we sorted the co-culture cells using fluorescence 
activated cell sorting (FACS) by pre-staining the breast cancer cells and MSCs with red and green dye 
Figure 1. Physical contact of MSCs with breast cancer cells activates Src. (a) Upper panel shows 
representative immunoblots of Src detected in BT-474 and 21MT-1 cells co-cultured with MSCs, transwell 
co-culture or MSCs-CM. (b) Lower panel shows respective densitometry of bands; monocultures of BT-
474 and 21MT-1 were used as control. Asterisks represent statistical significant differences in change in 
expression of Src in co-cultures samples compared with monoculture control. Data are mean ± SD; n = 3 
independent experiments; **p < 0.01 compared with control.
www.nature.com/scientificreports/
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Figure 2. Establishing patterned co-culture of breast cancer cells and MSCs. (a) Left, optical micrographs 
of breast cancer cells and MSCs cultured on various surfaces after 5 days (Scale bar, 500 μ m); Right, 
quantitative analysis of attachment of cells determined with MTT assay. Cells grown on TCPS were 
used as control. Mean ± SD; n = 3 independent experiments; **p < 0.01 compared with control. (b) Left, 
immunoblots show protein expression of specific markers of BT-474, 21MT-1 and MSCs on different 
surfaces. Right, respective densitometry of bands normalized with control after loading control (GAPDH) 
correction. Cells grown on TCPS served as control. (c) Scheme illustrating the approach for engineering 
patterned co-culture of breast cancer cells and MSCs (The scheme is not drawn to represent the true nature 
of the co-culture system) Fluorescent images of patterned monocultures of BT-474 and 21MT-1 (green) and 
patterned co-culture of breast cancer cells (green) and MSCs (red) after seeding MSCs (Scale bars- 200 μ m).
www.nature.com/scientificreports/
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prior to co-culture. Src expression in FACS sorted cells was examined using western blotting. To val-
idate the efficiency of FACS, the sorted cells were probed with breast cancer specific marker HER-2, 
and MSCs specific marker, CD166. Results indicated that the HER-2 expression and CD166 expression 
were observed only in sorted breast cancer cells and sorted MSCs, respectively (Supplementary Fig. 5). 
Compared to monoculture, transwell co-culture, and MSCs conditioned media treated breast cancer 
cells, patterned co-culture significantly (p < 0.05 and p < 0.01) increased Src phosphorylation at Y416 
(Src-pY416) (Fig. 3B and Supplementary Fig. 5), an indicator of Src activity6,7,36. Together, our data indi-
cate that physical contact of MSCs with breast cancer cells activates Src kinase activity in HER-2 over-
expressing breast cancer cells, and this is not observed in breast cancer cells in mono-culture, transwell 
co-culture, or those treated with conditioned media from MSCs.
MSCs Activates Pathways Regulating Tumor Growth and Trastuzumab Resistance. Src 
activation has been demonstrated to play a direct role in the progression of aggressive HER-2 positive 
breast cancer6,7. To explore the effect of MSCs on tumor growth, we examined whether MSCs in contact 
with tumor cells has any effect on HER-2 expression, an important biomarker and indicator of tumor 
growth and progression1,2. Immunostaining of HER-2 demonstrated increased fluorescence in patterned 
co-culture as compared to the monoculture and cancer cells exposed to MSC conditioned media (Fig. 4A 
Figure 3. MSCs induces Src activation in patterned co-culture and not in conditioned media. (a) 
Immunostaining of Src (FITC, green) and MSCs marker- CD166 (Cy3, red) in (i) patterned monoculture 
of breast cancer cells; (ii) Breast cancer cells exposed to MSCs-CM; (iii) patterned co-culture of breast 
cancer cells with MSCs; (iv) enlarged image of (iii). (b) Upper panel, immunobots show activation of Src 
in breast cancer cells sorted after co-culture with MSCs using FACS, and in breast cancer cells exposed to 
MSCs-CM and in transwell co-culture. Lower panel, quantification of band intensity to assess the relative 
phosphorylation of Src at tyrosine 416 position (Y416). Mean ± SD; n = 3 independent experiments; 
*p < 0.05 compared with monoculture; **p < 0.01 compared with monoculture.
www.nature.com/scientificreports/
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and Supplementary Fig. 4). Quantification of fluorescence intensity indicated higher HER-2 expression 
in breast cancer cells in co-culture compared to both monoculture and breast cancer cells exposed to 
MSCs-CM. To further confirm that MSCs mediated Src activation regulate HER-2, we examined the 
Figure 4. For legend see next page.
www.nature.com/scientificreports/
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protein expression in breast cancer cells after co-culture using western blotting (Fig.  4B). A notably 
increased HER-2 expression in both BT-474 and 21MT-1 cells were observed in co-culture with MSCs 
compared to monoculture and MSCs-CM treated cells. Also, upregulation of HER-2 expression was more 
prominent in 21MT-1 cells, which are derived from metastatic cancer patients, suggesting the potential 
role of MSCs in more aggressive tumors.
To investigate how MSCs mediated activation of Src regulates phosphatase and tension homolog 
(PTEN), we examined whether breast cancer cells in co-culture with MSCs may inhibit PTEN, since 
Src activation has recently been reported to promote loss of PTEN8. We observed reduced expression 
of PTEN in BT-474 and complete loss of PTEN in 21MT-1 cells in co-culture with MSCs. In contrast, 
no change was observed in BT-474 cells exposed to MSCs-CM or in transwell co-culture, however, sub-
stantial downregulation was observed in 21MT-1 cells exposed to MSCs-CM and in transwell co-culture 
(Fig. 4C and Supplementary Fig. 5). This suggests that PTEN loss is not limited to the physical contact 
of MSCs with breast cancer cells in more aggressive cancers. This data is significant; as for the first 
time a PTEN deficient breast cancer in vitro model has been generated without the use of chemical 
inhibitors37,38, matrix stiffness39, or silencing RNAs40,41, thus indicating that our co-culture model is a 
physiologically relevant model. PTEN is a well-known tumor suppressor, and loss of PTEN has long 
been associated with tumor progression and drug resistance42. Furthermore, several reports in differ-
ent tumor models have shown that PI3K/Akt signaling pathways become fundamental proliferative and 
survival pathways under PTEN loss or Src activation8,43. Thus, we investigated if physical contact of 
breast cancer cells with MSCs regulates these pathways. In our experimental settings, we observed ~2 
fold increase in PI3K expression in BT-474 cells and ~3 fold increase in 21MT-1 cells when co-cultured 
with MSCs (Fig.  4D). Correspondingly, we observed activation of AKT by phosphorylation at serine 
473 (AKT-pS473) in BT-474 as well as in 21MT-1. Significant increase (p < 0.01) in total AKT was also 
observed in BT-474 exposed to MSCs, in contrast no change in total AKT was observed in 21MT-1. 
Notably, no significant changes were observed in BT-474 and 21MT-1 cells exposed to MSCs-CM. These 
data are indicative of the role of MSCs mediated regulation of the proliferative and survival pathways of 
breast cancer cells where Src is activated and/or HER-2 is upregulated.
Breast Cancer Cells in Co-culture with MSCs Contribute to Trastuzumab Resistance. To 
investigate if the physical intimacy of MSCs may confer resistance to trastuzumab in breast cancer cells, 
we assessed the migratory potential of cancer cells in co-culture when exposed to the drug. Trastuzumab 
has been shown to inhibit cell migration in both in vitro and in vivo studies, however the drug loses this 
ability in drug resistant tumors3. In order to evaluate the effect of direct contact of MSC on breast cancer 
cells migration, we probed the migration capacity of BT-474 and 21MT-1 in mono-cultures, exposed 
with MSCs-CM, and co-cultures with MSCs in the presence of trastuzumab (Fig.  5A). A scratch was 
made in a sub-confluent cell monolayer and cells were allowed to migrate into the cell-free area. The 
distance moved by the cells in control, MSC-CM treated cells, and co-cultured plates, respectively, was 
compared when exposed to the drug. To distinguish the cell populations, breast cancer cells and MSCs 
were stained with green dye, CFDSE and red dye, PKH26 respectively. In the absence of trastuzumab, 
the co-culture of BT-474 and 21MT-1 cells with MSCs showed significantly (p < 0.001) higher migration 
after 48 h of co-culture as compared to the respective monocultures. On the other hand, only 21MT-1 
cells treated with MSCs-CM demonstrated significant migration as compared to monoculture (p < 0.05). 
When BT-474 mono-culture cells were exposed to Ttzm, there was no significant change in the migra-
tory property in mono-culture and MSCs-CM conditions but BT-474 in co-culture showed significantly 
(p < 0.01) higher migration when compared to untreated co-culture samples. In contrast, when 21MT-1 
mono-culture and MSC-CMs cells were exposed to Ttzm, there was no significant no signficiant inhi-
bition in the migratory potential while 21MT-1 in co-culture showed significantly (p < 0.05) even after 
exposed to Ttzm. This data suggest that direct interaction of MSCs with breast cancer cells promotes 
Figure 4. MSCs activates pathways regulating tumor growth and trastuzumab resistance. (a) Left, 
Immunostaining of HER-2 (Texas red) to assess the expression of HER-2 in patterned co-culture. Right, 
quantification of fluorescence intensity of HER-2 expression using imageJ. Mean ± SD; n = 3 independent 
experiments; **p < 0.01 compared with monoculture; ***p < 0.001 compared with monoculture. (b) 
Top, immunoblots of HER-2 expression in BT-474 and 21MT-1 cells sorted after co-culture with MSCs, 
and after exposed to MSCs-CM. Bottom, respective densitometry of HER-2 expression normalized with 
monoculture after GAPDH correction. Mean ± SD; n = 3 independent experiments; **p < 0.01 compared 
with monoculture. (c) Top, immunoblots of PTEN expression in BT-474 and 21MT-1 cells sorted after co-
culture with MSCs, transwell co-culture and after exposed to MSCs-CM. Bottom, respective densitometry 
of PTEN expression normalized with monoculture after GAPDH correction. Mean ± SD; n = 3 independent 
experiments; **p < 0.01 compared with monoculture. (d) Top, western blot analysis of PI3K, pAKT 
and AKT. Bottom, respective densitometry of bands normalized with monoculture after loading control 
(GAPDH) correction. Expression of pAKT was further normalized with AKT (pAKT/AKT). Data are 
mean ± SD; n = 3 independent experiments; *p < 0.05 compared with monoculture; **p < 0.01 compared 
with monoculture.
www.nature.com/scientificreports/
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Figure 5. Breast cancer cells in co-culture with MSCs contribute to trastuzumab resistance. (a) Migration 
assay data detailing the migration of cells out from a confluent monolayer onto a featureless scratch or 
wound. Left, representative fluorescent images of breast cancer cells (CFDSE, green) and breast cancer cells 
co-cultured with MSCs (PKH26, red) before and after treatment with trastuzumab (Ttzm) at time = 0 h 
and 48 h. Scale bar 500 μ m. Right, quantification of wound closure. The percentage of wound closure was 
determined by using following equation: % wound closure  =  [(Area @ t = 0–Area @ t = 48)/Area @ 
t = 0h]× 100%. Data are mean ± SD; n = 3 independent experiments; **p < 0.01 compared with untreated 
monoculture; ***p < 0.001 compared untreated monoculture; ^^p < 0.05 compared with random co-
culture; ^p < 0.01 compared with random co-culture. (b) MSCs in co-culture with breast cancer cells 
confer trastuzumab resistance. Left, western blot analysis of Ki67 in breast cancer cells sorted by FACS after 
co-culture with MSCs, and breast cancer cells exposed to MSCs-CM in the presence or absence of Ttzm. 
Right, respective densitometry of bands normalized with respective untreated group after loading control 
(GAPDH) correction. Mean ± SD; n = 3 independent experiments; *p < 0.05 compared with untreated 
monoculture. (c) Suggested model of trastuzumab resistance mediated by MSCs via activation of Src. Figure 
drawn by Dr. Amita Daverey.
www.nature.com/scientificreports/
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migration of breast cancer cells and potentially regulates the Ttzm responsiveness in breast tumor cells 
when in physical contact.
In the light of this data, we further validated the effect of MSCs-breast cancer cells interaction on 
trastuzumab resistance by determining Ki67, a clinical maker for the rate of proliferation in breast cancer 
cells and key hallmark of trastuzumab mechanism of action (Fig. 5B and Supplementary Fig. 6). Breast 
cancer cells were cultured as monocultures, co-cultures with MSCs, and MSC-CM treated groups in the 
presence or absence of trastuzumab for 48 h. Breast cancer cells in the co-culture system were separated 
using FACS and probed for Ki67, a proliferation marker. The Ki67 expression decreased significantly 
(p < 0.05) in BT-474 and 21MT-1 monocultures after trastuzumab treatment compared to untreated 
monocultures. However, no change in Ki67 expression was observed in BT-474 and 21MT-1 co-cultured 
with MSCs after trastuzumab treatment, thus indicating that the tumor cells are unresponsive to the 
drug. Interestingly, no significant effect was observed in Ki67 expression when BT-474 exposed to 
MSCs-CM treated with Ttzm but 21MT-1 exposed to MSCs-CM treated with Ttzm indicated decreased 
Ki67 expression. The differential behavior between Bt-474 and 21MT-1 might potentially be due to the 
different sources of the tumor cells, which needs further investigation.
Discussion
Trastuzumab is a highly specific, targeted cancer therapy that has brought valuable therapeutic benefits 
to HER-2-overexpressing cancer patients44. However, the limited response and drug resistance, even in 
patients with tumors expressing very high levels of HER-2, raises questions on the mechanisms of tras-
tuzumab resistance in patients. The possible mechanisms that contribute to the frequent development 
of resistance to trastuzumab are at its infant stages, and are an active area of investigation4,8. Recent 
studies have demonstrated that activation of Src is important during development of trastuzumab resist-
ance. Here, we report that the breast cancer cell in physical contact with MSCs elicit Src activation and 
regulates downstream trastuzumab resistance pathways (Fig. 5C). We developed a co-culture model to 
study the interaction between MSCs and breast cancer cells, and identified previously unexplored reg-
ulation of Src through MSCs in HER-2 positive breast cancer cells. The unique patterned co-culture 
model enables us to recreate the cell-cell communication underway in tumor development and progres-
sion. The model provides the ability to capture the temporal changes in the cell biology as the tumor 
develops through various stages. The significant advantages of our patterned co-cultures are: (1) the 
protein-free cell-culture environment reduces nonspecific function; (2) provides ease of visualization, 
patterned co-culture platform has several advantages over random co-cultures; (3) precise and consistent 
control of degree of contact between the cells (demonstrated in Supplementary Figure 4); and (4) the 
cancer cell-MSC interaction can be controlled by varying the percent coverage of the cells using different 
pattern dimensions to emulate different stages of a breast tumor. To validate the physiological relevance 
of this study, we used patient-derived HER-2 positive metastatic breast cancer cells (21MT-1) isolated 
from the metastatic pleural effusion. This finding led to the new concept that physical contact of MSCs 
is a key factor that contributes to trastuzumab’s resistance by activating Src. We also found that MSCs 
presence causes overexpression of HER-2 and loss of PTEN. This indicates that MSCs regulates the 
functional crosstalk between the HER-2 receptor and the PTEN tumor suppressor in breast cancer cells 
via Src. Src plays important oncogenic functions (e.g., inactivates PTEN) when bound to and activated 
by overexpressed HER-2, which contributes to the trastuzumab resistance. To our knowledge, no study 
has specifically investigated the role of MSCs in regulation of Src in breast cancer, which has been shown 
as common node for multiple pathways associated with growth, invasion and trastuzumab resistance of 
this disease.
In vitro and in vivo studies have demonstrated the role of Src in cellular growth and proliferation, 
angiogenesis, invasion and metastasis. The elevated expression of Src has been previously reported in 
majority of breast cancer tissues which is significantly associated with HER-2 status and metastatic dis-
ease6,7,45. Belsches-Jablonski et al. identified stable complex formation between Src and HER-2 in 13 breast 
cancer cell lines46. On the other hand role of MSCs on breast cancer progression remain unclear and 
controversial. It has been reported that bone marrow derived human MSCs can stimulate MCF-7 breast 
cancer cell proliferation in vitro and promote breast tumor metastasis in a xenograft model15–17. Recently, 
Clarke et al. showed the inhibition of migration and invasion in breast cancer cells, MDA-MB-231 and 
T47D, through immortalized MSC line RCB215747. Of note, they used co-cultured breast cancer cells in 
a transwell insert above MSCs or MSCs conditioned media, therefore, results obtained here are medi-
ated only through soluble factors. However, there are several reports that show that MSCs inhibited 
the growth of tumors in xenograft breast cancer model when co-inoculated with human cancer cells or 
administered intravenously to animals48,49. In contrast, Usha et al. documented that MSCs do not pro-
mote or inhibit the tumor growth and development in a clinically relevant mouse model50. We observed 
MSCs resulted in the overexpression of HER-2 expression in breast cancer cells in our co-culture model, 
however conditioned media or transwell co-culture did not have any effect on the HER-2 expression. 
This observation is corresponding to the Src activation, thus, increased expression of HER-2 and Src may 
have direct interaction which results in promoting the growth of breast cancer cells. Our study showed 
increased proliferation of breast cancer cells in co-culture systems as evident by increased expression of 
Ki67. Therefore, from our study and previous reports it is evident that the outcome of MSCs on tumor 
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growth and progression is dependent on the tumor types, the sources of MSCs and mouse models such 
as syngeneic versus xenogeneic graft.
Several studies based on pharmacological inhibitors of Src family tyrosine kinases indicate that Src 
activation is upstream of PI3K. In addition, PI3K has been shown to be a preferential substrate for Src 
and a major signaling hub downstream of HER-2. We demonstrated that activation of Src at Tyr416 not 
only activates AKT (Ser473) but also increased the activity of PI3K in breast cancer cells co-cultured 
with MSCs. In support to our findings, recent report has reported the activation of PI3K/AKT signal-
ing pathways mediated by Src activation in trastuzumab resistant breast cancer cells8. In addition, their 
data showed that increased Src phosphorylation at Tyr416 regulates the loss of PTEN. Interestingly, we 
observed PTEN loss in highly metastatic cell line 21MT-1 mediated through physical contact of MSCs 
with breast cancer cells as well as through soluble factors alone. In contrast, PTEN loss observed in 
BT-474 cells was primarily due to result of physical contact of MSCs with breast cancer cells. In con-
trast, Dasari et al. observed that the MSCs are able to upregulate PTEN simultaneously downregulating 
the PI3K/Akt pathway51. However, these studies were carried out on glioblastoma and human umbilical 
cord blood-derived MSCs which have possibly have a different synergistic pathway compared to breast 
tumors. To our knowledge, this is the first report that showed PTEN loss by MSCs in breast cancer cells 
without the use of chemical inhibitors37,38, matrix stiffness39, or silencing RNAs40,41. Since Src Tyr416 
served as a direct substrate for PTEN loss, it is possible that MSCs activates Src via knocking down the 
PTEN. However, we did not observe activation of Src in 21MT-1 through conditioned media or tran-
swell co-culture, thus, whether MSCs regulate Src independently or through PTEN loss remains to be 
explored. Earlier studies showed that loss of PTEN, Src activation and increased activity of PI3K/AKT 
pathways confer trastuzumab resistance to breast cancer cells8,42. In support of these studies, our wound 
healing data indicate that breast cancer cells harbor resistant to trastuzumab therapy in the presence of 
MSCs which was further confirmed by increased proliferation of breast cancer cells in co-cultures as 
compared to mono-culture systems.
In summary, our study identifies a systemic mechanism of resistance via interaction of breast cancer 
cells with MSCs by activation of Src and its downstream PI3K/AKT pathways. We have provided evi-
dence that the physical contact is important for breast cancer cells to develop drug resistance and enhance 
tumor growth, metastasis and drug resistance. To validate the physiological relevance of this study, we 
used patient-derived HER2+ metastatic breast cancer cells (21MT1) isolated from the metastatic pleural 
effusion. Our findings introduce important players to the field of drug resistance, and indicate targeting 
physical interaction of MSCs and breast cancer cells might be a possible strategy for drug resistant HER-2 
positive breast tumors. It should be noted that the MSC-mediated Src activation and trastuzumab resist-
ance mechanism detailed here is potentially one of the many possible tumor microenvironment-mediated 
drug resistance interactions. Our findings point to the tumor microenvironment as an important but 
understudied source of anticancer drug resistance. Moreover, the results suggest that such resistance 
mechanisms can be uncovered through the systematic dissection of interactions between tumors and 
their microenvironment. Future studies should therefore seek to identify such resistance mechanisms for 
all of the drugs that are in development, potentially leading to mechanism-based combination regimens 
to overcome drug resistance.
Materials and Methods
HER-2 overexpressed breast cancer cell lines, BT-474 and 21MT-1 were kindly provided by Drs. Hamid 
Band and Vimla Band (UNMC, USA). Adipose derived MSCs were obtained from American Type Culture 
Collection (ATCC). BT-474 cells were grown in complete α -MEM made up of α -MEM medium supple-
mented with 5% FBS, 1% L-glutamine, 100 U/mL penicillin G, 100 μ g/mL streptomycin, 20 mM HEPES, 
non-essential amino acids and sodium-pyruvate (complete α -MEM). 21MT-1 cells were developed by 
Dr. Vimla Band from a metastatic breast cancer patient and maintained in complete α -MEM, further 
supplemented with 12.5 ng/ml epidermal growth factor (EGF) and 1 ng/ml hydrocortisone. MSCs were 
grown in MSCGM (Lonza) supplemented with growth factors provided with kit. For all experiments 
MSCs were not used more than 3 passages. All cells were grown in the presence of 5% CO2 at 37 °C.
Two co-culture systems were utilized: (1) direct co-culture (random or patterned co-culture), (2) 
indirect co-culture (conditioned media from MSCs or transwell co-culture). For random co-culture, 
0.3 × 106 BCCs were seeded into per well of 6 well plate followed by seeding 0.1 × 106 MSCs on Day 2. 
BCCs were allowed to grow for 72 h in the presence of MSCs. For patterned co-culture, 0.6 × 106 BCCs 
were first seeded into per well of fabricated 6-well plate and allowed to grow for two days. After that, 
0.2 × 106 MSCs were added on day 2, cells were were allowed to grow for 72 h in co-culture. For condi-
tioned media (MSCs-CM) experiments, 0.5 × 106 MSCs were seeded into 60 mm petri dish and allowed 
to grow for 2 days. Conditioned media was collected from 80% confluent monolayer at passage 3 on Day 
2, and store at − 80 °C until use. MSCs-CM was added to the BCCs cultures on day 2 and allowed to 
expose to the MSCs-CM for 72 h. For transwell experiments, 30,000 BCCs per well were first seeded on 
the bottom of 24-well transwell cell culture system (Pore size 0.4 μ m; Costar Corp, USA) and allowed to 
grow for two days. On day 2, transwell insert were placed into wells of BCCs cultures, and 10,000 MSCs 
per well were seeded onto the membrane of transwell cell culture inserts. The cultures were allowed to 
grow for 72 h. For all co-culture systems, medium of BCCs was exchanged with co-culture media (1:1 
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ratio of BCCs medium and MSCs medium) on day 2. For all experiments monoculture of BCCs grown 
in co-culture media was used as control.
Wound healing assay. Cells were seeded as monocultures and co-cultures in a 6 well plate as 
described earlier in “co-culture” section. Cells were allowed to grow under permissive conditions until 
80% confluence and a wound was created using a sterile 10 μ l pipette tip. The wounded cells were washed 
three times with PBS to remove detached cells and the cells were incubated in co-culture media in the 
presence or absence of 20 μ g/ml trastuzumab, a kind gift from Genentech (South San Francisco, CA). The 
wound area at 0, 24 and 48 h after scratching was photographed using a microscopy system (Axiovert40 
Zeiss, Germany), and the cell-free wound area was measured using NIH Image J software. The percent-
age of wound closure was determined by using following equation:
% of wound closure = [(Area @ t = 0–Area @ t = 48)/Area @ t = 0h] × 100%
Statistics. Statistical analysis were made using GraphPad Instat 5.0 program (GraphPad Software, 
USA). Comaprison between each groups were determined using nonparametric One-Way-ANOVA and 
Student-Newman-Keuls Multiple Comparisons Test. Each value represents mean ± sd from minimum 
3 biological replicates. Statistical significance between two samples was determined by a P value of less 
than 0.05. P values of less than 0.05, 0.01, or 0.001 are described as *P < 0.05, **P < 0.01, or ***P < 0.001, 
respectively.
Please refer to SI Materials and Methods for detailed methods.
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